Rosiglitazone Does Not Show Major Hidden Cardiotoxicity in Models of Ischemia/Reperfusion but Abolishes Ischemic Preconditioning-Induced Antiarrhythmic Effects in Rats In Vivo

Clinical observations are highly inconsistent with the use of the antidiabetic rosiglitazone regarding its associated increased risk of myocardial infarction. This may be due to its hidden cardiotoxic properties that have only become evident during post-marketing studies. Therefore, we aimed to inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Bennet Y., Brenner, Gábor B., Kiss, Bernadett, Gergely, Tamás G., Sayour, Nabil V., Tian, Huimin, Makkos, András, Görbe, Anikó, Ferdinandy, Péter, Giricz, Zoltán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503202/
https://www.ncbi.nlm.nih.gov/pubmed/36145276
http://dx.doi.org/10.3390/ph15091055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503202/
https://www.ncbi.nlm.nih.gov/pubmed/36145276
http://dx.doi.org/10.3390/ph15091055

Ejemplares similares